Author

Ali Hussain

INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE ALPHA4BETA-7 INHIBITOR MORF-057 IN HEALTHY SUBJECTS
INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE ALPHA4BETA-7 INHIBITOR MORF-057 IN HEALTHY SUBJECTS

Ali Hussain  et al.

INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE ALPHA4BETA-7 INHIBITOR MORF-057 IN HEALTHY SUBJECTS
INCREASE IN CIRCULATING T AND B LYMPHOCYTE SUBSETS AFTER TREATMENT WITH THE POTENT, SELECTIVE, ORAL, SMALL MOLECULE ALPHA4BETA-7 INHIBITOR MORF-057 IN HEALTHY SUBJECTS

TRANSLATIONAL BIOMARKERS FOR SELECTIVE, ORAL, SMALL MOLECULE ?4?7 INHIBITOR MORF-057
TRANSLATIONAL BIOMARKERS FOR SELECTIVE, ORAL, SMALL MOLECULE ?4?7 INHIBITOR MORF-057

Ali Hussain  et al.

CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

Ali Hussain  et al.

Item 1 - 4 / 4
1